Century Therapeutics Financials - Benzinga

Century Therapeutics Inc

IPSCNASDAQ

Trade with Public

Trade with Public

$2.05

0.0251.23%

At close: Aug 31, 5:00 PM EST

$2.06

0.010.49%

After Hours: 7:18 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Century Therapeutics Financials

Century Therapeutics (IPSC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 55.26 percent increase over losses of $(0.38) per

Benzinga Newsdesk

PRO
Century Therapeutics Q1 EPS $(0.11) Beats $(0.17) Estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 31.25 percent. This is a 112.36 percent decrease over earnings of $0.89 per share

Benzinga Newsdesk

PRO
Century Therapeutics Q4 EPS $(0.25) Beats $(0.27) Estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 8.42 percent. This is a 41.86 percent increase over losses of $(0.43) per share

Benzinga Newsdesk

PRO
Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.34) by 18.34 percent. This is a 8.11 percent decrease over losses of $(0.37) per share

Benzinga Newsdesk

PRO
Century Therapeutics Q2 EPS $(0.38) Misses $(0.37) Estimate

Benzinga Newsdesk

PRO
Century Therapeutics Q1 EPS $0.89 Beats $0.16 Estimate, Sales $109.16M Beat $49.55M Estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.16 by 456.25 percent. This is a 297.78 percent increase over losses of $(0.45) per share

Benzinga Newsdesk